Related Experiment Videos

Treatment of HCV in patients with renal failure

Harmit Kalia1, Patricia M Lopez, Paul Martin

  • 1Division of Gastroenterology, UMDNJ-New Jersey Medical School, Newark, New Jersey, USA.

Archives of Medical Research
|July 7, 2007
PubMed

Insights

Hepatitis C virus (HCV) remains prevalent in chronic kidney disease (CKD) patients undergoing hemodialysis, leading to increased liver disease mortality and reduced transplant success. Early antiviral treatment shows promise for improving outcomes in these vulnerable populations.

Area of Science:

  • Nephrology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is common in patients with chronic kidney disease (CKD) on maintenance hemodialysis.
  • HCV infection is associated with higher mortality from liver disease and poorer outcomes after renal transplantation.
  • Current treatment options for HCV in CKD patients are limited due to potential complications.

Purpose of the Study:

  • To review the challenges and potential strategies for managing hepatitis C virus infection in patients with chronic kidney disease.
  • To evaluate the efficacy and safety of antiviral therapies, including interferon and ribavirin, in CKD patients and renal transplant recipients.

Main Methods:

  • Review of existing literature on HCV prevalence, management, and outcomes in CKD patients and renal transplant recipients.
  • Analysis of data regarding the use of interferon and ribavirin, including dosing, side effects, and efficacy.

Main Results:

  • HCV infection significantly increases mortality and reduces graft and patient survival in renal transplant recipients.
  • Interferon treatment before transplantation can lead to sustained viral response post-transplant.
  • Ribavirin is generally avoided in CKD due to hemolytic anemia, but reduced doses show promise with careful monitoring.

Conclusions:

  • HCV poses a significant threat to patients with CKD, impacting both dialysis survival and transplant success.
  • Antiviral therapy, particularly interferon, can be beneficial for renal transplant candidates and recipients.
  • Careful use of reduced-dose ribavirin may be a viable option for select CKD patients with close hematological monitoring.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...